Persistency rates for prostaglandin and other hypotensive eyedrops: Population-based study using pharmacy claims data

Clinical and Experimental Ophthalmology

Volumn 35, Issue 7, 2007, Pages 602-611

  Rait, Julian L ^a   Adena, Michael A ^b  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^b Pty Ltd   (Australia)

Author keywords

Ocular hypertension; Open angle glaucoma; Patient compliance; Pharmaceutical economics; Synthetic prostaglandins

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; LATANOPROST; LEVOBUNOLOL; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST;

ARTICLE; AUSTRALIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG COST; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; LIFE TABLE; PATIENT COMPLIANCE; POPULATION RESEARCH; RETROSPECTIVE STUDY;

ADRENERGIC AGENTS; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-AGONISTS; AUSTRALIA; CARBONIC ANHYDRASE INHIBITORS; COHORT STUDIES; GLAUCOMA; HUMANS; INSURANCE CLAIM REPORTING; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PATIENT COMPLIANCE; PHARMACEUTICAL SERVICES; PROSTAGLANDINS; RETROSPECTIVE STUDIES;

EID: 34848864557     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2007.01564.x     Document Type: Article

References (22)

1. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005; 11: 449-57.
2. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004; 137: S13-16.
3. Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care 2002; 8: S271-7.
4. Spooner JJ, Bullano MF, Ikeda LI et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care 2002; 8: S262-70.
5. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005; 112: 953-61.
6. Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 2005; 16: 114-21.
7. Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care 2002; 8: S255-61.
8. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: A population-based, retrospective study. Clin Ther 2003; 25: 1172-85.
9. Zhou Z, Althin R, Sforzolini BS, Dhawan R. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol 2004; 88: 1391-4.
10. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004; 137: S3-12.
11. Wilensky J, Fiscella RG, Carlson AM, Morris LS, Walt J. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006; 141: S28-33.
12. Carroll SC, Gaskin BJ, Goldberg I, Danesh-Meyer HV. Glaucoma prescribing trends in Australia and New Zealand. Clin Experiment Ophthalmol 2006; 34: 213-18.
13. Centrelink. A Guide to Centrelink Concession Cards. Accessed November 2005. Available from: http://www.centrelink.gov.au/internet/internet.nsf/ publications/co153.htm
14. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140: 598-606.
15. Rouland JF, Le Pen C, Benhaddi H et al. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years. Eur J Ophthalmol 2005; 15: 562-80.
16. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology 2005; 112: 1177-85.
17. Li N, Chen XM, Zhou Y, Wei ML, Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: Meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol 2006; 34: 755-64.
18. Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993; 116: 176-81.
19. Kass MA, Gordon M, Morley RE Jr, Meltzer DW, Goldberg JJ. Compliance with topical timolol treatment. Am J Ophthalmol 1987; 103: 188-93.
20. Tingey D, Bernard LM, Grima DT, Miller B, Lam A. Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension. Can J Ophthalmol 2005; 40: 161-9.
21. Bohn RL, Gurwitz JH, Yeomans SM et al. Which patients are treated for glaucoma? An observational analysis. J Glaucoma 2000; 9: 38-44.
22. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005; 112: 863-8.